Literature DB >> 16688597

Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients.

E Rota1, G Bellone, P Rocca, B Bergamasco, G Emanuelli, P Ferrero.   

Abstract

An inflammatory response has been hypothesised to be involved in the pathogenesis of primary dementias, above all Alzheimer's disease (AD). This study was aimed at evaluating interleukin (IL)-12 and a panel of related cytokine levels in paired CSF and sera of demented patients. IL-12 (p70 heterodimer and total IL-12 p40 chain), interferon (IFN)-gamma, IL-10 and transforming growth factor (TGF)-beta1 levels were measured in 30 patients with probable Alzheimer's disease (PrAD), 57 patients with other dementing disorders, including probable vascular dementia (PrVD), Parkinson's disease (PD) and normal pressure hydrocephalus (NPH), and 25 cognitively normal control subjects. In the presence of unchanged concentrations of IL-12, IFN-gamma and IL-10, the mean CSF level of TGF-beta1 and the correspondent TGF-beta1 index, but not the serum level, were significantly increased in PrAD compared to controls and PrVD, whereas no difference was found vs. NPH and PD. Our results support the pathophysiological role of TGF-beta1 system in AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16688597     DOI: 10.1007/s10072-006-0562-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  46 in total

1.  Increased T-cell reactivity and elevated levels of CD8+ memory T-cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: implications for immunotherapy.

Authors:  Katharina Schindowski; Anne Eckert; Jürgen Peters; Corinna Gorriz; Uta Schramm; Thomas Weinandi; Konrad Maurer; Lutz Frölich; Walter E Müller
Journal:  Neuromolecular Med       Date:  2007-10-26       Impact factor: 3.843

2.  Age-dependent changes on TGFβ1 Smad3 pathway modify the pattern of microglial cell activation.

Authors:  Juan E Tichauer; Betsi Flores; Bernardita Soler; Laura Eugenín-von Bernhardi; Gigliola Ramírez; Rommy von Bernhardi
Journal:  Brain Behav Immun       Date:  2013-12-29       Impact factor: 7.217

3.  TGF-β1 Regulation of P-JNK and L-Type Calcium Channel Cav1.2 in Cortical Neurons.

Authors:  Zhenning Liu; Jiangtao Sheng; Guoyi Peng; Jinhua Yang; Weiqiang Chen; Kangsheng Li
Journal:  J Mol Neurosci       Date:  2018-02-08       Impact factor: 3.444

Review 4.  Biomarkers of oxidative damage and inflammation in Alzheimer's disease.

Authors:  Douglas Galasko; Thomas J Montine
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

5.  Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).

Authors:  Takashi Sasayama; Satoshi Nakamizo; Masamitsu Nishihara; Atsufumi Kawamura; Hirotomo Tanaka; Katsu Mizukawa; Shigeru Miyake; Masaaki Taniguchi; Kohkichi Hosoda; Eiji Kohmura
Journal:  Neuro Oncol       Date:  2011-12-12       Impact factor: 12.300

6.  Amyloid-β Activates Microglia and Regulates Protein Expression in a Manner Similar to Prions.

Authors:  Jian Tu; Baian Chen; Lifeng Yang; Kezong Qi; Jing Lu; Deming Zhao
Journal:  J Mol Neurosci       Date:  2015-04-14       Impact factor: 3.444

7.  Single-Base Resolution Mapping of 5-Hydroxymethylcytosine Modifications in Hippocampus of Alzheimer's Disease Subjects.

Authors:  Elizabeth M Ellison; Melissa A Bradley-Whitman; Mark A Lovell
Journal:  J Mol Neurosci       Date:  2017-09-02       Impact factor: 3.444

Review 8.  Glial cell dysregulation: a new perspective on Alzheimer disease.

Authors:  Rommy von Bernhardi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

Review 9.  Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease.

Authors:  Milan Fiala; Robert Veerhuis
Journal:  Exp Gerontol       Date:  2009-08-21       Impact factor: 4.032

10.  Intrathecal corticosteroids might slow Alzheimer's disease progression.

Authors:  Joseph Martin Alisky
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.